May 6, 2019 by Brian Orelli, PhDExelixis Expands Its SalesThe biotech produced solid top-line growth spurred by a new approval for Cabometyx.
May 6, 2019 by Brian Orelli, PhDAlnylam Pharmaceuticals Continues Onpattro Launch With More to ComeAdditional drug approvals and launches are on the way.
May 2, 2019 by Brian Orelli, PhDVertex Pharmaceuticals Looks to Jump From 18,000 Patients to 68,000The biotech's cystic fibrosis treatment potential is far from over.
May 1, 2019 by Brian Orelli, PhDBioMarin Isn't a "Gene Therapy Company"Despite the biotech's move into gene therapy, its bread and butter are still paying the bills.
Apr 30, 2019 by Brian Orelli, PhDSeattle Genetics' "Growth Is Tracking Well"The biotech is on track to hit its 2019 revenue guidance for Adceris sales to increase 28% to 34%.
Apr 29, 2019 by Brian Orelli, PhDCelgene's Final Earnings Report?Depending on when in the third quarter its deal with Bristol-Myers Squibb closes, this could be the last report of the beloved big biotech.
Apr 29, 2019 by Brian Orelli, PhDNatus Medical Continues Its RestructuringIt's a rebuilding year for the medical device maker.
Apr 26, 2019 by Brian Orelli, PhDAlkermes Looks Ahead to GrowthGeneric competition is dragging down revenue this year, but it has FDA approvals in the wings.
Apr 25, 2019 by Brian Orelli, PhDBiogen Looks to 23 Clinical Programs for GrowthFirst-quarter sales were up 11%, but future growth is less certain.
Apr 25, 2019 by Brian Orelli, PhDHere's Why Shares of Alkermes Sank TodaySales of the drugmaker's schizophrenia drug Aristada disappointed investors.
Apr 23, 2019 by Brian Orelli, PhDKidney-Cancer Market: Good for Patients, Hard for InvestorsDrugmakers battle for patients.
Apr 22, 2019 by Brian Orelli, PhDHere's Why Sientra's Shares Got a Lift TodayThe FDA approved a design change for the company's Opus breast implants.
Apr 17, 2019 by Brian Orelli, PhDHere's Why Shares of bluebird bio Slumped TodayNo-news anxiety-selling seems to be to blame for the biotech's woes.
Apr 17, 2019 by Brian Orelli, PhDHere's Why Ionis Pharmaceuticals Slumped TodayInformation from competitors and a collaborator sent the high-flying biotech lower.
Apr 12, 2019 by Brian Orelli, PhDHere's Why Biohaven Pharmaceutical Jumped 20% TodayRumor has it that the drugmaker is up for sale.
Apr 5, 2019 by Brian Orelli, PhDHere's Why LivaNova Plummeted TodayThe medical-device company posted tepid preliminary first-quarter revenue.
Apr 4, 2019 by Brian Orelli, PhD1 Biotech That Biogen Should Buy ... but Probably Won'tThe drugmaker has $4.9 billion in the bank.
Mar 28, 2019 by Brian Orelli, PhDHere's Why EyePoint Pharmaceuticals Saw Its Share Price Drop TodayA secondary offering raised some cash but diluted current shareholders.
Mar 20, 2019 by Brian Orelli, PhDDiplomat Pharmacy Looks to RebuildSome stumbles will make this a challenging year for the specialty pharmacy.
Mar 19, 2019 by Brian Orelli, PhDHere's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial DataAs is often the case with drug development, the devil is in the details.
